Suggested remit: To appraise the clinical and cost effectiveness of osimertinib within its marketing authorisation as maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer (NSCLC) which has not progressed after platinum based chemoradiation.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6223
Provisional Schedule
- Expected publication:
- 29 April 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email TATeam3@nice.org.uk
- External Assessment Group:
- Liverpool Reviews and Implementation Group, University of Liverpool
Stakeholders
- Companies sponsors
- AstraZeneca (osimertinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- EGFR Positive
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- AstraZeneca (durvalumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Comittee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 January 2026 | Note added to the project documents |
| 20 November 2025 | Committee meeting: 2 |
| 29 September 2025 | Note - Note added to the project documents |
| 28 August 2025 - 18 September 2025 | Draft guidance |
| 19 June 2025 | Committee meeting |
| 19 June 2025 | Declaration of interests |
| 04 April 2025 | Note - Note added to the project documents |
| 30 October 2024 | Invitation to participate |
| 10 July 2024 - 07 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6223 |
| 10 July 2024 | In progress. Scoping commencing |
| 14 March 2024 | Note - Note added to the project documents |
| 26 January 2024 | Note - Note added to the project documents |
| 31 July 2023 | Note - Note added to the project documents |
| 16 December 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 28 November 2022 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual